Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management

被引：6

作者：

Jazayeri, Seyed Behzad ^{[1
]}

Srivastava, Abhishek ^{[2
]}

Shore, Neal ^{[2
]}

机构：

[1] Univ Florida, Dept Urol, Jacksonville, FL USA

[2] Genesis Care, Myrtle Beach, SC 29579 USA

来源：

CURRENT OPINION IN UROLOGY | 2022年 / 32卷 / 03期

关键词：

abiraterone; apalutamide; darolutamide; enzalutamide; prostate cancer; ACETATE PLUS PREDNISONE; RANDOMIZED PHASE-II; ABIRATERONE ACETATE; DOUBLE-BLIND; SURVIVAL ANALYSIS; ENZALUTAMIDE; TRIAL; MEN; APALUTAMIDE;

D O I：

10.1097/MOU.0000000000000984

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review We review the published literature on the indications of second-generation androgen receptor inhibitors, Poly(ADP-Ribose) Polymerase (PARP) inhibitors, combination therapies, and their evolution throughout the advanced prostate cancer continuum. Recent findings Enzalutamide trials have published data supporting its use in metastatic hormone-sensitive prostate cancer (mHSPC), nonmetastatic castration-resistant prostate cancer (nmCRPC), and metastatic castration-resistant prostate cancer (mCRPC). Apalutamide trials have supported its indication for mHSPC and nmCRPC. Darolutamide trials currently support its use for nmCRPC. Abiraterone trials have supported its use in mCRPC and mHSPC. Olaparib and rucaparib have shown clinical benefit in heavily pretreated patients with mCRPC and DNA repair mutation genes. Phase 3 trials and peer-reviewed literature demonstrate that enzalutamide, apalutamide, and darolutamide prolong overall survival (OS) in men with nmCRPC. Abiraterone, enzalutamide, and apalutamide improve OS in men with mHSPC. Abiraterone and enzalutamide have data supporting improvement in OS in men with mCRPC

引用

页码：283 / 291

页数：9

共 48 条

[1] Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration [J].

Abida, Wassim ;

Patnaik, Akash ;

Campbell, David ;

Shapiro, Jeremy ;

Bryce, Alan H. ;

McDermott, Ray ;

Sautois, Brieuc ;

Vogelzang, Nicholas J. ;

Bambury, Richard M. ;

Voog, Eric ;

Zhang, Jingsong ;

Piulats, Josep M. ;

Ryan, Charles J. ;

Merseburger, Axel S. ;

Daugaard, Gedske ;

Heidenreich, Axel ;

Fizazi, Karim ;

Higano, Celestia S. ;

Krieger, Laurence E. ;

Sternberg, Cora N. ;

Watkins, Simon P. ;

Despain, Darrin ;

Simmons, Andrew D. ;

Loehr, Andrea ;

Dowson, Melanie ;

Golsorkhi, Tony ;

Chowdhury, Simon .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (32) :3763-+

[2]

[Anonymous], 2021, JCO, DOI DOI 10.1200/JCO.2021.39.15_SUPPL.5000

[3] Final overall survival (OS) analysis from ARCHES: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) [J].

Armstrong, A. J. ;

Iguchi, T. ;

Azad, A. A. ;

Szmulewitz, R. Z. ;

Holzbeierlein, J. ;

Villers, A. ;

Alcaraz, A. ;

Alekseev, B. Y. ;

Shore, N. D. ;

Petrylak, D. P. ;

Rosbrook, B. ;

Zohren, F. ;

Yamada, S. ;

Haas, G. P. ;

Stenzl, A. .

ANNALS OF ONCOLOGY, 2021, 32 :S1300-S1301

[4] ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer [J].

Armstrong, Andrew J. ;

Szmulewitz, Russell Z. ;

Petrylak, Daniel P. ;

Holzbeierlein, Jeffrey ;

Villers, Arnauld ;

Azad, Arun ;

Alcaraz, Antonio ;

Alekseev, Boris ;

Iguchi, Taro ;

Shore, Neal D. ;

Rosbrook, Brad ;

Sugg, Jennifer ;

Baron, Benoit ;

Chen, Lucy ;

Stenzl, Arnulf .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (32) :2974-+

[5] Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol [J].

Attard, Gerhardt ;

Murphy, Laura ;

Clarke, Noel W. ;

Cross, William ;

Jones, Robert J. ;

Parker, Christopher C. ;

Gillessen, Silke ;

Cook, Adrian ;

Brawley, Chris ;

Amos, Claire L. ;

Atako, Nafisah ;

Pugh, Cheryl ;

Buckner, Michelle ;

Chowdhury, Simon ;

Malik, Zafar ;

Russell, J. Martin ;

Gilson, Clare ;

Rush, Hannah ;

Bowen, Jo ;

Lydon, Anna ;

Pedley, Ian ;

O'Sullivan, Joe M. ;

Birtle, Alison ;

Gale, Joanna ;

Srihari, Narayanan ;

Thomas, Carys ;

Tanguay, Jacob ;

Wagstaff, John ;

Das, Prantik ;

Gray, Emma ;

Alzoueb, Mymoona ;

Parikh, Omi ;

Robinson, Angus ;

Syndikus, Isabel ;

Wylie, James ;

Zarkar, Anjali ;

Thalmann, George ;

de Bono, Johann S. ;

Dearnaley, David P. ;

Mason, Malcolm D. ;

Gilbert, Duncan ;

Langley, Ruth E. ;

Millman, Robin ;

Matheson, David ;

Sydes, Matthew R. ;

Brown, Louise C. ;

Parmar, Mahesh K. B. ;

James, Nicholas D. .

LANCET, 2022, 399 (10323) :447-460

[6] Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment [J].

Attard, Gerhardt ;

Borre, Michael ;

Gurney, Howard ;

Loriot, Yohann ;

Andresen-Daniil, Corina ;

Kalleda, Ranjith ;

Trinh Pham ;

Taplin, Mary-Ellen .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (25) :2639-+

[7]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[8] Mechanisms of resistance in castration-resistant prostate cancer (CRPC) [J].

Chandrasekar, Thenappan ;

Yang, Joy C. ;

Gao, Allen C. ;

Evans, Christopher P. .

TRANSLATIONAL ANDROLOGY AND UROLOGY, 2015, 4 (03) :365-380

[9] Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study [J].

Chi, Kim N. ;

Chowdhury, Simon ;

Bjartell, Anders ;

Byung Ha Chung ;

Gomes, Andrea J. Pereira de Santana ;

Given, Robert ;

Juarez, Alvaro ;

Merseburger, Axel S. ;

Ozguroglu, Mustafa ;

Uemura, Hirotsugu ;

Ye, Dingwei ;

Brookman-May, Sabine ;

Mundle, Suneel D. ;

McCarthy, Sharon A. ;

Larsen, Julie S. ;

Sun, Weili ;

Bevans, Katherine B. ;

Zhang, Ke ;

Bandyopadhyay, Nibedita ;

Agarwal, Neeraj .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (20) :2294-+

[10] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer [J].

Chi, Kim N. ;

Agarwal, Neeraj ;

Bjartell, Anders ;

Chung, Byung Ha ;

Pereira de Santana Gomes, Andrea J. ;

Given, Robert ;

Juarez Soto, Alvaro ;

Merseburger, Axel S. ;

Ozguroglu, Mustafa ;

Uemura, Hirotsugu ;

Ye, Dingwei ;

Deprince, Kris ;

Naini, Vahid ;

Li, Jinhui ;

Cheng, Shinta ;

Yu, Margaret K. ;

Zhang, Ke ;

Larsen, Julie S. ;

McCarthy, Sharon ;

Chowdhury, Simon .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (01) :13-24

← 1 2 3 4 5 →